23 Nov 2021 07:00
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Notice of results
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces it will issue its unaudited interim results for the six months ended 30 September 2021 on Tuesday, 7 December 2021.
Enquiries:
Evgen Pharma plc www.evgen.com | via Walbrook | |
Dr Huw Jones, CEO | ||
Richard Moulson, CFO | ||
finnCap www.finncap.com | +44 (0)20 7220 0500 | |
Geoff Nash / Teddy Whiley (Corporate Finance) | ||
Alice Lane (ECM) | ||
Walbrook PR | +44 (0)20 7933 87870 or evgen@walbrookpr.com | |
Anna Dunphy / Phillip Marriage | +44 (0)7876 741 001 / +44 (0)7867 984 082 | |
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/